ASBP logo

Aspire Biopharma Holdings, Inc.

ASBP
Healthcare|Medical - Pharmaceuticals|US
$8.09
+1.33 (+19.67%)
Tangible Book / Share
$11.33
Cash / Share
$11.72

Earnings History

Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Aug 13, 2026$-1.00—$63.1K—
May 15, 2026$-20.57—$28.4K—
Mar 30, 2026$-3.15—$4.3K—
Nov 14, 2025$-0.04—$1.9K—
Aug 13, 2025$-0.04———
May 14, 2025$-16.80———
Apr 7, 2025$-0.28———
Nov 14, 2024$-0.02———

News

Aspire-Lakewood Holdings Board Approves $10 Million Share Repurchase Program

Brings total authorized repurchase to $10 million Reflects leadership's view that Aspire-Lakewood's share price does not reflect the Company's financial strength or long-term growth opportunity Increased authorization supported by strength of newly acquired Dura Control Systems Corp's (DCSC) full year 2025 and six months ended June 30, 2026 revenue of approximately $209.5 million and Adjusted EBITDA1 of $22.3 million and approximately $103.9 million and Adjusted EBITDA1 of $10.5 million, respect…

Sep 9, 2026accessnewswire.com
Aspire Biopharma Holdings, INC. Announces Corporate Name Change To Aspire-Lakewood Holdings, Inc.

ESTERO, FL / ACCESS Newswire / September 8, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) ("Aspire" or the "Company"), today announced that it has changed its corporate name from "Aspire Biopharma Holdings, Inc." to "Aspire-Lakewood Holdings, Inc." The name change is effective upon the filing of a Certificate of Amendment to the Company's Certificate of Incorporation with the Secretary of State of the State of Delaware. The Company's ticker symbol, "ASBP", will remain unchanged.

Sep 8, 2026accessnewswire.com
Aspire Biopharma Holdings, Inc., to Present at Sidoti Virtual Investor Conference August 19th

ESTERO, FL / ACCESS Newswire / August 13, 2026 / Aspire Biopharma Holdings, Inc. (Nasdaq:ASBP) ("Aspire" or the "Company"), today announced that management will be present and host one-on-one meetings with investors at Sidoti & Company's Micro-Cap Virtual Investor Conference taking place on August 19-20, 2026. Management plans to discuss its clinical and commercial development pipeline and its recently closed acquisition of Dura Driver Control Systems, a leading global automotive supplier with a…

Aug 13, 2026accessnewswire.com
Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Acquisition represents a transformative milestone for Aspire, positioning the Company to rapidly evolve into a diversified, high-revenue enterprise Adds an established global brand with scale in large and growing markets driven by trends in vehicle and mobility control systems Augments revenue growth profile and diversifies Aspires' development and commercial portfolio with new high growth business Expected to immediately improve path to profitability ESTERO, FL / ACCESS Newswire / August 10, 20…

Aug 10, 2026accessnewswire.com